Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. The Massachusetts company has reported the results of the phase 3 MAESTRO ...

The pharmaceutical company received clearance from the Subject Expert Committee (SEC) of CDSCO to conduct bioequivalence (‘BE ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Nausea and diarrhea were the most common adverse events and occurred approximately twice as often in the resmetirom patients as in the placebo patients. The drug was approved on an accelerated ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved ...

We have now 1 FDA-approved medication called resmetirom, and we are anticipating the FDA approval of semaglutide at the end of this year. However, we have many unmet needs in the field ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...